Cortexolone 17α‐propionate 1% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double‐blind comparative study vs. placebo and tretinoin 0·05% cream

  title={Cortexolone 17$\alpha$‐propionate 1\% cream, a new potent antiandrogen for topical treatment of acne vulgaris. A pilot randomized, double‐blind comparative study vs. placebo and tretinoin 0·05\% cream},
  author={Viorel Trifu and George Sonn Tiplica and E Naumescu and L Zalupca and Luigi Moro and Giuseppe Celasco},
  journal={British Journal of Dermatology},
Background  Acne vulgaris is a disorder of the pilosebaceous unit in which the androgens contribute to its onset and persistence. The use of antiandrogens is therefore potentially effective; however, antiandrogens for topical use are not available on the market. Cortexolone 17α‐propionate (CB‐03‐01; Cosmo S.p.A, Lainate, Italy) is a new potent topical antiandrogen potentially useful in acne vulgaris. 

Clascoterone 1% cream in acne vulgaris: a profile of its use

Application of clascoterone 1% cream twice daily for 12 weeks was effective and generally well tolerated in acne vulgaris patients, with a tolerability profile similar to that of the vehicle.

Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream

Clascoterone 1% cream (Winlevi) offers a new and exciting treatment approach for a difficult and common skin condition such as acne vulgaris and will hopefully provoke investigations into other androgen receptor antagonists with similar or better efficacy.

Clascoterone: a new topical anti‐androgen for acne management

Clascoterone seems a promising topical drug with a novel mechanism of action that could be added to the armamentarium of therapies for acne.

Novel pharmacological approaches for the treatment of acne vulgaris.

The authors discuss and evaluate the pathogenic pathways related to the mechanisms of action of novel molecules, which are currently under investigation for the treatment of acne vulgaris.

Clascoterone: First Approval

The milestones in the development of clascoterone leading to this first approval for the topical treatment of acne vulgaris are summarized.

Solodyn and Updates on Topical and Oral Therapies for Acne

The most recent developments in acne pathophysiology are summarized, as the concern for antibiotic resistance grows, and treatments involving nonantibiotic therapies are growing in popularity.

Clascoterone: A Novel Topical Androgen Receptor Inhibitor for the Treatment of Acne

Clascoterone, a novel topical androgen receptor inhibitor, is a safe and effective treatment option for patients with acne vulgaris.

Novel pharmacological approaches for the treatment of acne vulgaris

The authors believe that there will likely be a decline in the use of antibiotics for controlling P. acnes colonization and targeting the inflammation cascade, and Retinoic acid metabolism-blocking agents and IL-1α inhibitors have the potential to become legitimate alternative options to retinoid therapy in the management of infundibular dyskeratosis.

New and emerging drugs for the treatment of acne vulgaris in adolescents

The novel treatment modalities that have surfaced in consequence of new knowledge obtained in acne pathogenesis, including Selective RAR-agonists, have the potential of becoming an alternative to the currently available retinoid therapy in the management of infundibular dyskeratosis with a better safety profile.

New Developments in Topical Acne Therapy

Recently approved topical acne treatments, as well as those currently in clinical trials, include Trifarotene, a novel fourth-generation retinoid, which has demonstrated improved tolerability compared with existing topical retinoids.



Topical retinoids in acne – an evidence‐based overview

Topical retinoids are important tools in the management of acne because they act against comedones and microcomedones and have direct anti‐inflammatory effects. The substances approved for acne

A combined analysis of 2 randomized clinical studies of tretinoin gel 0.05% for the treatment of acne.

Tretinoin gel 0.05% applied once daily is a well-tolerated and effective therapy for acne vulgaris and is associated with a low incidence of skin-related AEs.

Comparison of topical clindamycin phosphate, benzoyl peroxide, and a combination of the two for the treatment of acne vulgaris

Cutaneous side‐effects were greatest with benzoyl peroxide alone during the early weeks of treatment, while the combination therapy displayed no greater incidence of redness, scaling, or itching than clindamycin phosphate alone.

Tretinoin microsphere gel in facial acne vulgaris: a meta-analysis.

Tretinoin microsphere gel 0.04% was significantly superior to the vehicle gel in reducing both inflammatory and noninflammatory lesions over the 12-week treatment period, and produced a higher successful treatment rate than the vehicle Gel.

Update and Future of Hormonal Therapy in Acne

Recent research over the past several years has unraveled some of the details regarding the way that the skin and sebaceous glands synthesize and metabolize hormones, providing an impetus for future drug discovery in the hormonal treatment of acne.

Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity.

The present data show that the topical administration of finasteride causes local inhibition of sebaceous gland growth in both the costovertebral organs and ears, however, as demonstrated by the similar inhibitory effect in the contralateral untreated side and the reduced weight of the dorsal and ventral lobes of the prostate and seminal vesicles, Finasteride and flutamide both exert significant systemic effects.

A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04% in the treatment of acne vulgaris in adults.

This double-blinded, randomized, vehicle-controlled, multicenter, parallel-group, 12-week, phase 4 study was conducted in adults with mild to moderate acne vulgaris with no statistically significant differences between treatment groups for any measured tolerability parameter.

The assessment of acne vulgaris—the Leeds technique

Two simple, reproducible scoring systems for assessing acne severity are described, and the technical problems which could invalidate either technique are emphasized.

Rook's Textbook of Dermatology

Rook's textbook of dermatology , Rook's textbooks of dermatologist, کتابخانه مرکزی دانشگاه ایران.